Identification of a novel ligand binding residue Arg38(1.35) in the human gonadotropin-releasing hormone receptor

Molecular Pharmacology

Volumn 73, Issue 1, 2008, Pages 75-81

  Stewart, Alan J ^a   Sellar, Robin ^a   Wilson, Donald J ^a   Millar, Robert P ^a,b   Lu, Zhi Liang ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CARBONYL DERIVATIVE; CETRORELIX; GLYCINAMIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; INOSITOL PHOSPHATE; LYSINE; PROLINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HYDROGEN BOND; LIGAND BINDING; MOLECULAR MODEL; MUTAGENESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; WILD TYPE;

ARGININE; BINDING SITES; HUMANS; LIGANDS; RECEPTORS, LHRH;

EID: 37349030902     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.040816     Document Type: Article

References (40)

1. B receptor. Biochemistry 38:6043-6055.
2. Ballesteros JA, Shi L, and Javitch JA (2001) Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structurefunction analysis of rhodopsin-like receptors. Mol Pharmacol 60:1-19.
3. Brooks BR, Bruccoleri RE, Olason BD, States DJ, Swaminathan S, and Karplus M (1983) CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comp Chem 4:187-217.
4. Casper RF (1991) Clinical uses of gonadotropin-releasing hormone analogues. Can Med Assoc J 144:153-158.
5. th Annual Meeting of the Endocrine Society; 2007 June 2-5; Toronto, Ontario, Canada; pp 1-369, The Endocrine Society, Chevy Chase, MD.
6. 102 of the gonadotropin-releasing hormone receptor is a critical determinant of potency for agonists containing C-terminal glycinamide. J Biol Chem 271:15510-15514.
7. Favre N, Fanelli F, Missotten M, Nichols A, Wilson J, di Tiani M, Rommel C, and Scheer A (2005) The DRY motif as a molecular switch of the human oxytocin receptor. Biochemistry 44:9990-10008.
8. Flanagan CA, Becker II, Davidson JS, Wakefield IK, Zhou W, Sealfon SC, and Millar RP (1994) Glutamate 301 of the mouse gonadotropin-releasing hormone receptor confers specificity for arginine 8 of mammalian gonadotropin-releasing hormone. J Biol Chem 269:22636-22641.
9. 261(98) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction. Biochemistry 39:8133-8141.
10. Fromme BJ, Katz AA, Roeske RW, Millar RP, and Flanagan CA (2001) Role of aspartate7.32(302) of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. Mol Pharmacol 60:1280-1287.
11. Gründker C, Völker P, and Emons G (2001) Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142:2369-2380.
12. 1a vasopressin receptor provides two independent epitopes required for high-affinity agonist binding and signaling. Mol Endocrinol 19:2871-2881.
13. Hoffmann SH, ter Laak TT, Kühne R, Reiländer H, and Beckers T (2000) Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol Endocrinol 14:1099-1115.
14. Hövelmann S, Hoffmann SH, Kühne R, ter Laak T, Reiländer H, and Beckers T (2002) Impact of aromatic residues within transmembrane helix 6 of the human gonadotropin-releasing hormone receptor upon agonist and antagonist binding. Biochemistry 41:1129-1136.
15. Hulme EC, Lu ZL, Ward SD, Allman K, and Curtis CA (1999) The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol 375:247-260.
16. Janovick JA, Maya-Nunez G, and Conn PM (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87:3255-3262.
17. Kaiser UB, Conn PM, and Chin WW (1997) Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 18:46-70.
18. Krsmanovic LZ, Mores N, Navarro CE, Arora KK, and Catt KJ (2003) An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. Proc Natl Acad Sci U S A 100:2969-2974.
19. s proteins in gonadotropin-releasing hormone receptor-mediated signaling in LbetaT2 cells. J Biol Chem 277:32099-32108.
20. Lu ZL, Coetsee M, White CD, and Millar RP (2007) Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. J Biol Chem 282:17921-17929.
21. 1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling. Mol Pharmacol 51:234-241.
22. Lu ZL, Gallagher R, Seller R, Coetsee M, and Millar RP (2005) Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations. J Biol Chem 280:29796-29803.
23. 1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis. J Biol Chem 274:7309-7315.
24. Lu ZL, Saldanha JW, and Hulme EC (2002) Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 23:140-146.
25. Mamputha S, Lu ZL, Roeske RW, Millar RP, Katz AA, and Flanagan CA (2007) Conserved Amino acid residues that are important for ligand binding in the type II GnRH receptor are required for high potency of GnRH II at the type II GnRH receptor. Mol Endocrinol 21:281-292.
26. Marco E, Foucaud M, Langer I, Escrieut C, Tikhonova IG, and Foumy D (2007) Mechanism of activation of a G-protein coupled receptor, the human cholecystokinin-2 receptor. J Biol Chem 282:28779-28790.
27. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, and Millar RP (2004) Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 64:7533-7544.
28. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, and Maudsley SR (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25:235-275.
29. Millar RP, Pawson AJ, Morgan K, Rissman E, and Lu ZL (2007) Diversity of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol, in press.
30. Oksche A, Leder G, Valet S, Platzer M, Hasse K, Geist S, Krause G, Rosenthal A, and Rosenthal W (2002) Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity. Mol Endocrinol 16:799-813.
31. Ruf F, Fink MY, and Sealfon SC (2003) Structure of the GnRH receptor-stimulated signaling network: insights from genomics. Front Neuroendocrinol 24:181-199.
32. Salom D, Lodowski DT, Stenkamp RE, Le Trong I, Golczak M, Jastrzebska B, Harris T, Ballesteros JA, and Palczewski K (2006) Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci U S A 103:16123-16128.
33. Sealfon SC, Weinstein H, and Millar RP (1997) Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 18: 180-205.
34. Silvente-Poirot S, Escrieut C, and Wank SA (1998) Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54:364-371.
35. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, and Leurs R (2007) Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47:53-87.
36. Söderhäll JA, Polymeropoulos EE, Paulini K, Günther E, and Kühne R (2005) Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor. Biochem Biophys Res Commun 333:568-582.
37. q/11-mediated signal transduction pathways: Evidence from loop fragment transfection in GGH3 cells. Endocrinology 139:2472-2478.
38. Wesley VJ, Hawtin SR, Howard HC, and Wheatley M (2002) Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor. Biochemistry 41:5086-5092.
39. Xu W, Campillo M, Pardo L, Kim de Riel J, and Liu-Chen LY (2005) The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions. Biochemistry 44:16014-16025.
40. Zhou W, Rodic V, Kitanovic S, Flanagan CA, Chi L, Weinstein H, Maayani S, Millar RP, and Sealfon SC (1995) A locus of the gonadotropin-releasing hormone receptor that differentiates agonist and antagonist binding sites. J Biol Chem 270:18853-18857.